rs11309117
- chr2-47414420-TAAAAAAAAAAAAAAAAAAA-T
- chr2-47414420-TAAAAAAAAAAAAAAAAAAA-TA
- chr2-47414420-TAAAAAAAAAAAAAAAAAAA-TAA
- chr2-47414420-TAAAAAAAAAAAAAAAAAAA-TAAA
- chr2-47414420-TAAAAAAAAAAAAAAAAAAA-TAAAA
- chr2-47414420-TAAAAAAAAAAAAAAAAAAA-TAAAAA
- chr2-47414420-TAAAAAAAAAAAAAAAAAAA-TAAAAAA
- chr2-47414420-TAAAAAAAAAAAAAAAAAAA-TAAAAAAA
- chr2-47414420-TAAAAAAAAAAAAAAAAAAA-TAAAAAAAA
- chr2-47414420-TAAAAAAAAAAAAAAAAAAA-TAAAAAAAAA
- chr2-47414420-TAAAAAAAAAAAAAAAAAAA-TAAAAAAAAAA
- chr2-47414420-TAAAAAAAAAAAAAAAAAAA-TAAAAAAAAAAA
- chr2-47414420-TAAAAAAAAAAAAAAAAAAA-TAAAAAAAAAAAA
- chr2-47414420-TAAAAAAAAAAAAAAAAAAA-TAAAAAAAAAAAAA
- chr2-47414420-TAAAAAAAAAAAAAAAAAAA-TAAAAAAAAAAAAAA
- chr2-47414420-TAAAAAAAAAAAAAAAAAAA-TAAAAAAAAAAAAAAA
- chr2-47414420-TAAAAAAAAAAAAAAAAAAA-TAAAAAAAAAAAAAAAA
- chr2-47414420-TAAAAAAAAAAAAAAAAAAA-TAAAAAAAAAAAAAAAAA
- chr2-47414420-TAAAAAAAAAAAAAAAAAAA-TAAAAAAAAAAAAAAAAAA
- chr2-47414420-TAAAAAAAAAAAAAAAAAAA-TAAAAAAAAAAAAAAAAAAAA
- chr2-47414420-TAAAAAAAAAAAAAAAAAAA-TAAAAAAAAAAAAAAAAAAAAA
- chr2-47414420-TAAAAAAAAAAAAAAAAAAA-TAAAAAAAAAAAAAAAAAAAAAA
- chr2-47414420-TAAAAAAAAAAAAAAAAAAA-TAAAAAAAAAAAAAAAAAAAAAAA
- chr2-47414420-TAAAAAAAAAAAAAAAAAAA-TAAAAAAAAAAAAAAAAAAAAAAAA
- chr2-47414420-TAAAAAAAAAAAAAAAAAAA-TAAAAAAAAAAAAAAAAAAAAAAAAA
- chr2-47414420-TAAAAAAAAAAAAAAAAAAA-TAAAAAAAAAAAAAAAAAAAAAAAAAA
- chr2-47414420-TAAAAAAAAAAAAAAAAAAA-TAAAAAAAAAAAAAAAAAAAAAAAAAAA
- chr2-47414420-TAAAAAAAAAAAAAAAAAAA-TAAAAAAAAAAAAAAAAAAAAAAAAAAAA
- chr2-47414420-TAAAAAAAAAAAAAAAAAAA-TAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
- chr2-47414420-TAAAAAAAAAAAAAAAAAAA-TAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
- chr2-47414420-TAAAAAAAAAAAAAAAAAAA-TAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
- chr2-47414420-TAAAAAAAAAAAAAAAAAAA-TAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
- chr2-47414420-TAAAAAAAAAAAAAAAAAAA-TAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
- chr2-47414420-TAAAAAAAAAAAAAAAAAAA-TAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
- chr2-47414420-TAAAAAAAAAAAAAAAAAAA-TAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
- chr2-47414420-TAAAAAAAAAAAAAAAAAAA-TAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
- chr2-47414420-TAAAAAAAAAAAAAAAAAAA-TAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
- chr2-47414420-TAAAAAAAAAAAAAAAAAAA-TAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
- chr2-47414420-TAAAAAAAAAAAAAAAAAAA-TAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
- chr2-47414420-TAAAAAAAAAAAAAAAAAAA-TAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
- chr2-47414420-TAAAAAAAAAAAAAAAAAAA-TAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
- chr2-47414420-TAAAAAAAAAAAAAAAAAAA-TAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
- chr2-47414420-TAAAAAAAAAAAAAAAAAAA-TAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
Variant summary
Our verdict is Likely benign. The variant received -2 ACMG points: 0P and 2B. BP6_Moderate
The NM_000251.3(MSH2):c.942+11_942+29delAAAAAAAAAAAAAAAAAAA variant causes a intron change. The variant allele was found at a frequency of 0.00000305 in 982,182 control chromosomes in the GnomAD database, with no homozygous occurrence. It is difficult to determine the true allele frequency of this variant because it is of type DEL_BIG, and the frequency of such variant types in population databases may be underestimated and unreliable. Variant has been reported in ClinVar as Likely benign (★).
Frequency
Consequence
NM_000251.3 intron
Scores
Clinical Significance
Conservation
Publications
- Lynch syndromeInheritance: AD Classification: DEFINITIVE, SUPPORTIVE Submitted by: G2P, ClinGen, Orphanet
- Lynch syndrome 1Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: Labcorp Genetics (formerly Invitae), Genomics England PanelApp, Ambry Genetics
- Muir-Torre syndromeInheritance: AD Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Genomics England PanelApp, Orphanet, G2P
- mismatch repair cancer syndrome 1Inheritance: AR Classification: DEFINITIVE, SUPPORTIVE Submitted by: ClinGen, Orphanet
- mismatch repair cancer syndrome 2Inheritance: AR Classification: DEFINITIVE, STRONG Submitted by: Labcorp Genetics (formerly Invitae), G2P
- ovarian cancerInheritance: AD Classification: STRONG Submitted by: Genomics England PanelApp
- malignant pancreatic neoplasmInheritance: AD Classification: MODERATE Submitted by: Genomics England PanelApp
- prostate cancerInheritance: AD Classification: MODERATE Submitted by: Ambry Genetics
- rhabdomyosarcomaInheritance: AR Classification: MODERATE Submitted by: Genomics England PanelApp
- breast cancerInheritance: AD Classification: NO_KNOWN Submitted by: Ambry Genetics
- hereditary breast carcinomaInheritance: AD Classification: NO_KNOWN Submitted by: ClinGen
Genome browser will be placed here
ACMG classification
Our verdict: Likely_benign. The variant received -2 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes Cov.: 0
GnomAD4 exome AF: 0.00000305 AC: 3AN: 982182Hom.: 0 AF XY: 0.00000205 AC XY: 1AN XY: 488170 show subpopulations
Age Distribution
GnomAD4 genome Cov.: 0
ClinVar
Submissions by phenotype
Lynch syndrome Benign:1
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at